Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases

Introduction: Plasminogen activator inhibitor-1 (PAI-1) is critical in thrombus formation and inflammation. Although these are essential pathological features of cardiovascular diseases, the effects of PAI-1 inhibition against the development of cardiovascular remodeling have not been well studied. Areas covered: The review explores the therapeutic value of PAI-1 in the progression of various cardiovascular diseases. To date, the authors have reported that a novel PAI-1 inhibitor suppressed the development of experimental autoimmune myocarditis, vascular remodeling after arterial injury, and heart transplant rejection using rodent models. Pathologically, the PAI-1 inhibitor improved histological remodeling of myocardium and arteries with suppression of inflammation and thrombus formation. Expert opinion: PAI-1 inhibitors appear to exhibit potent effects on the prevention of adverse tissue remodeling. However, PAI-1 is a multifunctional protein and more research is needed to further elucidate the association between PAI-1 expression and cardiovascular disease.

[1]  S. Kaul,et al.  Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. , 2010, Journal of the American College of Cardiology.

[2]  U. Kalnins,et al.  Heparin-Coated Stent Placement for the Treatment of Stenoses in Small Coronary Arteries of Symptomatic Patients , 2003, Circulation.

[3]  G. Thiene,et al.  Immunosuppressive Therapy for Active Lymphocytic Myocarditis: Virological and Immunologic Profile of Responders Versus Nonresponders , 2003, Circulation.

[4]  Rémy Ricoux,et al.  Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. , 2002, The American journal of pathology.

[5]  B Meier,et al.  Restenosis after successful coronary angioplasty in patients with single-vessel disease. , 1986, Circulation.

[6]  M. Duffy,et al.  The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. , 2004, Clinical biochemistry.

[7]  C. Bode,et al.  Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. , 2000, The Journal of clinical endocrinology and metabolism.

[8]  M. Cuzner,et al.  A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. , 2005, The American journal of pathology.

[9]  B. Sobel,et al.  Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. , 1996, Circulation.

[10]  J. Mason,et al.  Advances in the understanding of myocarditis. , 2001, Circulation.

[11]  D. Collen,et al.  On the role of plasminogen activator inhibitor‐1 in adipose tissue development and insulin resistance in mice , 2005, Journal of thrombosis and haemostasis : JTH.

[12]  G. Maurer,et al.  Plasminogen activator inhibitor‐1 predicts coronary in‐stent restenosis of drug‐eluting stents , 2008, Journal of thrombosis and haemostasis : JTH.

[13]  P. Carmeliet,et al.  Inhibition of Urokinase-Type Plasminogen Activator or Matrix Metalloproteinases Prevents Cardiac Injury and Dysfunction During Viral Myocarditis , 2006, Circulation.

[14]  G. Schernthaner,et al.  Cardiovascular risk and thiazolidinediones—what do meta‐analyses really tell us? , 2010, Diabetes, obesity & metabolism.

[15]  R. Benza,et al.  Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  N. Gorlatova,et al.  Characterization and comparative evaluation of a structurally unique PAI‐1 inhibitor exhibiting oral in‐vivo efficacy , 2004, Journal of thrombosis and haemostasis : JTH.

[17]  P. Carmeliet,et al.  Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. , 1997, Circulation.

[18]  T. van der Poll,et al.  Two-way interactions between inflammation and coagulation. , 2005, Trends in cardiovascular medicine.

[19]  A. Itai,et al.  The Effects of Pharmacologic Plasminogen Activator Inhibitor-1 Inhibition in Acute and Chronic Rejection in Murine Cardiac Allografts , 2011, Transplantation.

[20]  T. Verbeuren,et al.  S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood. , 2008, Thrombosis research.

[21]  G. Maurer,et al.  Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. , 2002, Journal of molecular and cellular cardiology.

[22]  R. Baglini,et al.  Restenosis after NIR stent implantation. , 2002, Minerva cardioangiologica.

[23]  J. Overgaard,et al.  Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. , 2007, Lung cancer.

[24]  N. Kohno,et al.  Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis , 2010, Thorax.

[25]  Li-jun Ma,et al.  PAI-1 and kidney fibrosis. , 2009, Frontiers in bioscience.

[26]  H. Ohmizu,et al.  Design, synthesis, and evaluation of orally active inhibitors of plasminogen activator inhibitor-1 (PAI-1) production. , 2008, Bioorganic & medicinal chemistry letters.

[27]  F. Rosendaal,et al.  Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. , 2010, Blood.

[28]  T. Miyata,et al.  Structure-activity relationships of new 2-acylamino-3-thiophenecarboxylic acid dimers as plasminogen activator inhibitor-1 inhibitors. , 2010, Chemical & pharmaceutical bulletin.

[29]  M. Borggrefe,et al.  Effect of Atorvastatin on Haemostasis, Fibrinolysis and Inflammation in Normocholesterolaemic Patients with Coronary Artery Disease , 2010, Clinical drug investigation.

[30]  V. Barak,et al.  The Relationship of Plasminogen Activator Inhibitor-1 Levels to the ST Deviation Pattern of Acute Myocardial Infarction , 2008, Cardiology.

[31]  F. Fernández‐Avilés,et al.  Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. , 2007, European heart journal.

[32]  P. Carmeliet,et al.  Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. , 2003, Blood.

[33]  H. Hauner,et al.  Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes , 2000, Diabetologia.

[34]  M. Makuuchi,et al.  Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis , 2002, Nature Medicine.

[35]  I. Juhan-vague,et al.  Contribution of PAI-1 in cardiovascular pathology. , 2004, Archives des maladies du coeur et des vaisseaux.

[36]  R. Westrick,et al.  Plasminogen activator inhibitor-1 in vascular thrombosis. , 2007, Current drug targets.

[37]  F. Werf.  Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial , 1999, The Lancet.

[38]  Y. Aso.  Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. , 2007, Frontiers in bioscience : a journal and virtual library.

[39]  G. Maurer,et al.  Plasminogen Activator Inhibitor 1 Expression is Regulated by the Inflammatory Mediators Interleukin-1α, Tumor Necrosis Factor-α, Transforming Growth Factor-β and Oncostatin M in Human Cardiac Myocytes ☆ , 2002 .

[40]  H. Schultheiss,et al.  Myocardial Remodeling in Viral Heart Disease: Possible Interactions Between Inflammatory Mediators and MMP-TIMP System , 2004, Heart Failure Reviews.

[41]  J. Bauer,et al.  WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregation. , 2003, Biochemical and biophysical research communications.

[42]  A. Itai,et al.  A specific inhibitor of plasminogen activator inhibitor-1 suppresses rat autoimmune myocarditis. , 2008, Expert opinion on therapeutic targets.

[43]  H. Ha,et al.  The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases , 2009, Nature Reviews Nephrology.

[44]  Yue-xiang Chen,et al.  Adenovirus-mediated transfer of siRNA against PAI-1 mRNA ameliorates hepatic fibrosis in rats. , 2009, Journal of hepatology.

[45]  T. Watanabe,et al.  Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function. , 1999, Biochemical and biophysical research communications.

[46]  H. Ohmizu,et al.  Synthesis and evaluation of 1,4-diphenylbutadiene derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) production. , 2010, Bioorganic & medicinal chemistry.

[47]  B. Strauss,et al.  Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. , 1999, Circulation.

[48]  A. Itai,et al.  The effects of pharmacological PAI-1 inhibition on thrombus formation and neointima formation after arterial injury , 2008, Expert opinion on therapeutic targets.

[49]  S. Kaul,et al.  Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. , 2010, Circulation.

[50]  Assent investigators.  Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction , 2001, The Lancet.

[51]  C. Bode,et al.  Plasminogen Activator Inhibitor Type-1 (PAI-1) and its Role in Cardiovascular Disease , 1999, Thrombosis and Haemostasis.

[52]  M. Nangaku,et al.  Inhibition of Plasminogen Activator Inhibitor-1: Its Mechanism and Effectiveness on Coagulation and Fibrosis , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[53]  D R Holmes.  In-stent restenosis. , 2001, Reviews in cardiovascular medicine.

[54]  P. Armstrong,et al.  Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial , 2006, The Lancet.

[55]  H. Schultheiss,et al.  Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. , 2003, Circulation.

[56]  M. Marinšek,et al.  A Randomized Trial Comparing the Effect of Ramipril and Losartan in Survivors of ST-Elevation Myocardial Infarction , 2009, The Journal of international medical research.

[57]  H. Elokdah,et al.  Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic Acid], a Novel Plasminogen Activator Inhibitor-1 Inhibitor, in a Canine Model of Coronary Artery Thrombosis , 2005, Journal of Pharmacology and Experimental Therapeutics.

[58]  C. Ibarra,et al.  The Contribution of the Exosite Residues of Plasminogen Activator Inhibitor-1 to Proteinase Inhibition* , 2004, Journal of Biological Chemistry.

[59]  R. Benza,et al.  Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease. , 1998, Circulation.

[60]  G. Krishnamurthy,et al.  Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. , 2004, Journal of medicinal chemistry.

[61]  H. Ha,et al.  Positive Feedback Loop between Plasminogen Activator Inhibitor-1 and Transforming Growth Factor-Beta1 during Renal Fibrosis in Diabetes , 2009, American Journal of Nephrology.

[62]  D. Vaughan,et al.  Pharmacological Inhibition and Genetic Deficiency of Plasminogen Activator Inhibitor-1 Attenuates Angiotensin II/Salt-Induced Aortic Remodeling , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[63]  H. Schultheiss,et al.  Interferon- (cid:1) Treatment Eliminates Cardiotropic Viruses and Improves Left Ventricular Function in Patients With Myocardial Persistence of Viral Genomes and Left Ventricular Dysfunction , 2003 .

[64]  K. Washington,et al.  Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. , 2006, Blood.

[65]  T. Miyata,et al.  A Novel Inhibitor of Plasminogen Activator Inhibitor-1 Provides Antithrombotic Benefits Devoid of Bleeding Effect in Nonhuman Primates , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.